

## DANA-FARBER CANCER INSTITUTE

Department of Medical Oncology

Matthew L. Meyerson, M.D., Ph.D.

Professor of Pathology, Harvard Medical School  
Director, Center for Cancer Genome Discovery, DFCI  
Senior Associate Member, Broad Institute



Contact:

Tel.: 617-632-4768

E-mail: [matthew\\_meyerson@dfci.harvard.edu](mailto:matthew_meyerson@dfci.harvard.edu)

Web Site:

<http://research4.dfci.harvard.edu/meyersonlab/>

Bio:

The Meyerson laboratory is focused on cancer genome discovery and particularly lung cancer pathogenesis. Together with Drs. Bill Sellers, Bruce Johnson and Pasi Janne, the Meyerson group identified somatic mutations in the epidermal growth factor gene, *EGFR*, in lung adenocarcinomas, that predict response to the EGFR kinase inhibitors, gefitinib and erlotinib. The Meyerson group and collaborators have also discovered other activated kinase genes in cancer, including *JAK2* in polycythemia vera, *FGFR2* in endometrial cancer, *ALK* in neuroblastoma, and *DDR2* and *FGFR1* in squamous cell lung cancer.

The laboratory has pioneered technical and computational approaches for cancer genome research, including methods for copy number determination with single nucleotide polymorphism (SNP) arrays, leading to identification of oncogenes including *NKX2-1*, *SOX2*, and *MCL1*. In addition, the Meyerson group performed the first next-generation sequencing analysis of cancer DNA and developed the computational subtraction approach to discovery of novel disease-causing microbes.

Dr. Meyerson plays a leading role in “The Cancer Genome Atlas” (TCGA), as principal investigator of the Genome Characterization Center at the Broad Institute, focused on copy number and structural alterations. He co-chairs the lung cancer working group with Drs. Steve Baylin and Ramaswamy Govindan. Dr. Meyerson and Dr. Bill Hahn direct the Center for Cancer Genome Discovery at Dana-Farber.

Dr. Meyerson serves as Professor of Pathology at Harvard Medical School and a Senior Associate Member at the Broad Institute. He has been awarded the Paul Marks Prize in Cancer Research and the AACR Team Science Award.